CTLA4 and cancer: Immunotherapy, specifically targeting immune checkpoint molecules like programmed cell death protein-1 (PD-1), programmed death-ligand 1 (PD-L1) inhibitors, and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), has revolutionized cancer treatment by enhancing the immune response against tumors.